Shahrooz Rabizadeh, Ph.D.
4516 California NanoSystems Institute310-983-1046 | 310-206-2921 fax
- B.S., University of California, Los Angeles, 1992
- Ph.D., University of California, Los Angeles, 1999
- Postdoctoral Research Fellow, Harvard University/Massachusetts General Hospital, 1999-2002
The mission of our laboratory is to collaboratively
innovate and rapidly develop novel medically-applicable tools and
technologies. The pursuit of
innovative solutions is often energized by the interconnection of otherwise
disparate scientific disciplines and technologies. Befitting this
interdisciplinary philosophy, we have partnered with material scientists and
engineers, chemists, and biologists to make medically-relevant discoveries in
our lab (the Abraxis/CNSI Collaborative Laboratory). And the resultants of our collaborative
projects have potential downstream applications as therapeutics, diagnostics,
and medical devices.
Personally, my passion for interdisciplinary biotechnology-based research developed in my postdoctoral training with Prof. Brian Seed (Harvard Med School & Mass Gen Hosp) and expressed itself at the Buck Institute, where my colleague Dr. Kayvan Niazi and I directed a translational unit focused on delivering next-generation therapeutics and inventing cutting-edge tools for biomedical application. Prior to our arrival at Abraxis and CNSI, Kayvan and I applied nanotechnology to molecular biology, immunology, and cell biology and arrived at potential solutions for cancer and fresh approaches to discovering therapeutics for neurological and infectious diseases. At Abraxis, grasping the complexity of all that entails the generation of a clinical product has completed our rudimentary understanding of drug/device development. These principles combined with our academic/translational experiences guide us in effectively steering ongoing and prospective collaborative and proprietary (Abraxis) projects.
- Kar U.K., Jiang J., Champion C.I., Salehi S., Srivastava M., Sharma S., Rabizadeh S., Niazi K., Kickhoefer V., Rome L.H., Kelly K.A. "Vault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of mice." PLoS One. 2012;7(7):e38553. Epub 2012 Jul 11.
- Fombonne J., Rabizadeh S., Banwait S., Mehlen P., Bredesen D.E., "Selective vulnerability in Alzheimer's disease: amyloid precursor protein and p75(NTR) interaction," Ann Neurol. 2009 Mar;65(3):294-303.
- Bredesen D.E., Rabizadeh S., "APP-based neuroprotective strategies," Curr Alzheimer Res. 2007 Dec;4(5):541-3.
- Niazi K.R., Ochoa M.T., Sieling P.A., Rooke N.E., Peter A.K., Mollahan P., Dickey M., Rabizadeh S., Rea T.H., Modlin R.L., "Activiation of human CD4+ T cells by targeting MHC class II epitopes to endosomal compartments using human CD1 tail sequences," Immunology. 2007 Dec;122(4):522-31. Epub 2007 Jul 16.
- Ting A, Lichtenthaler S., Xavier R., Na S.Y., Rabizadeh S., Holmes T., Seed B., "Large-scale screens for cDNAs with in vivo activity," Novatris Found Symp. 2006;267:219-29; discussion 229-30.
- Xavier R., Rabizadeh S., Ishiguro K., Andre N., Ortiz J.B., Wachtel H., Morris D.G., Lopz-Ilasaca M., Shaw A.C., Swat W., Seed B., "Discs large (Dlg1) complexes in lymphocyte activation," J Cell Biol. 2004 Jul 19;166(2):173-8.
- Rabizadeh S., Xavier R.J., Ishiguro K., Bernabeortiz J., Lopz-Ilasaca M., Khokhlatchev A., Mollahan P., Pfeifer G.P., Avruch J., Seed B., "The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death," J Biol Chem. 2004 Jul 9;279(28):29247-54. Epub 2004 Apr. 9
- Bredesen D.E., Mehlen P., Rabizadeh S., "Apoptosis and dependence receptors: a molecular basis for cellular addiction," Physiol Rev. 2004 Apr;84(2):411-30. Review.
- Castro-Obregon S., Roa R.V., del Rio G., Chen S.F., Poksay K.S., Rabizadeh S., Vesce S., Zhang X.K., Swanson R.A., Bredesen D.E., "Altnerative nonapoptotic programmed cell death; mediation by arrestin 2, ERK2, and Nur77," J Biol Chem. 2004 Apr 23;279(17):17543-53. Epub 2004 Feb 9.
- Rabizadeh S., Bredesen D.E., "Ten years on: mediation of cell death by the common neurotrophin receptor p75(NTR)," Cytokin Growth Factor Rev. 2003 Jun-Aug;14(3-4):225-39. Review.